Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Lung Diseases, Obstructive
Description
Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent. MeSH
Hierarchy View
Subtype Terms (3)
Asthma
551 drugs (203 approved, 348 experimental)
Bronchitis
72 drugs (40 approved, 32 experimental)
Pulmonary Disease, Chronic Obstructive
426 drugs (192 approved, 234 experimental)
Phase 3 Indicated Drugs (5)
Phase 2 Indicated Drugs (7)
Other Experimental Indicated Drugs (1)
Organization Involved with Phase 4 Indications (167)
Anhui College of Traditional Chinese Medicine
Armed Police General Hospital, P. R. China
Baqiyatallah Medical Sciences University
Blekinge County Council Hospital
Catalan Society of Family Medicine
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Complejo Hospitalario Carlos Haya
Complejo Hospitalario de Especialidades Juan Ramón Jimenez
Dutch Health Care Insurance Board
East West Medical Research Institute
Father Sean O'Sullivan Research Centre
Federal University of Health Science of Porto Alegre
Flight Attendant Medical Research Institute
Fondo de Investigacion Sanitaria
Fundació Investigació de les Illes Balears
Hellenic Institute for the Study of Sepsis
Hospital of South West Jutland
Hospital Universitario Puerto Real
Hospital Universitario Virgen Macarena
Huazhong University of Science and Technology
Institute of Sera and Vaccines RAS, Moscow
Isala Clinics, Zwolle, The Netherlands
Katholieke Universiteit Leuven
Liaoning Province North Hospital
Los Angeles Biomedical Research Institute
National Health and Medical Research Council, Australia
National Institute for Health Research, United Kingdom
Netherlands Organisation for Scientific Research
People's Liberation Army of China
Rundo International Pharmaceutical Research & Development Co.,Ltd.
Russian Academy of Medical Sciences
Sociedad Española de Neumología y Cirugía Torácica
Spanish Research Center for Respiratory Diseases
Taipei Veteran General hospital
Organization Involved with Phase 3 Indications (107)
Ache Laboratorios Farmaceuticos S.A.
Canadian Institutes of Health Research (CIHR)
Cantonal Hospital of St. Gallen
Centers for Medicare and Medicaid Services
Clinical Sciences Center University Hospital Aintree
DongWha Pharmaceutical Company
Federal University of Rio de Janeiro
Health Sciences University Sureyyapasa Chest Diseases and Chest Surgery Hospital
Henan University of Traditional Chinese Medicine
Hopitaux Universitaires Paris Centre
Hospital Son Espases, Palma Mallorca
Liaoning Hospital of Traditional Chinese Medicine
National Cancer Institute (NCI)
National Health Service, United Kingdom
National Heart, Lung, and Blood Institute (NHLBI)
National Science and Technology Development Agency, Thailand
Nova Scotia Health Research Foundation
Oregon Health and Science University
Patient-Centered Outcomes Research Institute
Pontifícia Universidade Católica do Paraná
Organization Involved with Phase 2 Indications (120)
Adams Respiratory Therapeutics
Azienda Ospedaliera Antonio Cardarelli
Bangabandhu Sheikh Mujib Medical University
Centre for General Practice for Clinical Trials Unit, Inala
Fondazione Don Carlo Gnocchi Onlus
GeneWorld Co., Ltd., Ho Chi Minh
Icahn School of Medicine at Mount Sinai
Institute of Medicinal Molecular Design, Inc.
Institut fuer Atemwegsforschung GmbH, Wiesbaden, Germany
Institut für Atemwegsforschung GmbH
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
King Edward VII Hospital, Windsor
Medical University of South Carolina
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Environmental Health Sciences (NIEHS)
Nguyen Tri Phuong Hospital, Ho Chi Minh city, Viet Nam
Northern Ireland Clinical Trials Unit
Peninsula Chest Clinic, Frankston
Philipps University of Marburg
Pulmonary Associates, Phoenix, AZ
Respiratory Research Foundation, Toorak Gardens
State University of New York, Buffalo
St Joseph's Medical Center, Towson, MD
Organization Involved with Phase 1 Indications (30)
Organization Involved with Other Experimental Indications (61)
Aristotle University of Thessaloniki
Chinese Academy of Medical Sciences
Fundación Neumologica Colombiana
Guangzhou Panyu Central Hospital
Hamilton Health Sciences Corporation
Hoosier Cancer Research Network
Instituto de Molestias Cardiovasculares
Lillehammer Hospital for Rheumatic Diseases
Lillehammer University College
Micro-Tech (Nanjing) Co., Ltd.
Minnesota Veterans Medical Research and Education Foundation
NATIONAL ASSOCIATION OF GENERAL PRACTITIONERS IN BULGARIA
National Science Centre, Poland
Norwegian School of Sport Sciences
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
The Royal Bournemouth Hospital
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
